Giiant Pharma
Giiant Pharma Inc. is a preclinical-stage biotech company focused on developing gut-restricted, tissue-specific small molecule therapeutics for inflammatory bowel diseases (IBD). Their mission is to improve IBD drug tolerability through precision delivery technology, aiming to become a leader in GI targeted drug delivery with a focus on safety and local action.
Industries
Nr. of Employees
small (1-50)
Products
Gut-targeted prodrug delivery platform
A technology approach that uses microbiota-mediated activation and chemical/formulation design to achieve colon-specific release of orally administered small-molecule prodrugs with limited systemic exposure.
Lead preclinical colon-specific PDE4 inhibitor prodrug
A microbiota-activated, orally administered prodrug candidate designed to provide local PDE4 inhibitory activity in the colon for inflammatory bowel disease while minimizing systemic exposure.
Gut-targeted prodrug delivery platform
A technology approach that uses microbiota-mediated activation and chemical/formulation design to achieve colon-specific release of orally administered small-molecule prodrugs with limited systemic exposure.
Lead preclinical colon-specific PDE4 inhibitor prodrug
A microbiota-activated, orally administered prodrug candidate designed to provide local PDE4 inhibitory activity in the colon for inflammatory bowel disease while minimizing systemic exposure.
Services
Coordination and execution of nonclinical toxicology and pharmacology studies, and preparation of regulatory filings required for investigational new drug submissions.
Formulation selection, solid form strategy and bioavailability optimization to prepare oral small-molecule candidates for GLP toxicology and clinical translation.
Collaborative development, licensing or research partnerships to co-develop gut-restricted small-molecule therapies and accelerate programs toward clinical proof-of-concept.
Coordination and execution of nonclinical toxicology and pharmacology studies, and preparation of regulatory filings required for investigational new drug submissions.
Formulation selection, solid form strategy and bioavailability optimization to prepare oral small-molecule candidates for GLP toxicology and clinical translation.
Collaborative development, licensing or research partnerships to co-develop gut-restricted small-molecule therapies and accelerate programs toward clinical proof-of-concept.
Expertise Areas
- Colon-targeted drug delivery
- Microbiota-activated prodrug strategies
- Small-molecule medicinal chemistry
- Preclinical IND-enabling development
Key Technologies
- Microbiota-triggered prodrug chemistries
- Colon-specific oral delivery strategies
- Small-molecule lead optimization
- Oral formulation and bioavailability enhancement
News & Updates
Giiant Pharma Inc. announced that it will receive up to US$ 500,000 from the US Crohn’s and Colitis Foundation to support the development of GT-2108, a gut-restricted PDE4 inhibitor prodrug for ulcerative colitis.
Giiant Pharma announced an additional financing of $1.25 million to support the development of its lead program GT-2108 for IBD, originating from the work of former Merck Frosst scientists.
Giiant Pharma Inc. announced that it will receive up to US$ 500,000 from the US Crohn’s and Colitis Foundation to support the development of GT-2108, a gut-restricted PDE4 inhibitor prodrug for ulcerative colitis.
Giiant Pharma announced an additional financing of $1.25 million to support the development of its lead program GT-2108 for IBD, originating from the work of former Merck Frosst scientists.